FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Study Questions Some Accelerated Approval Uses

Yale University researchers say giving sponsors extended periods to complete post-accelerated approval studies may not be justified.

Medical Devices

Research Uncovers Cyber Security Flaws in Device Software

New research uncovers numerous software vulnerabilities in medical devices.

Medical Devices

Electronic Submission of eSTAR 510(k)s Needed: Consultant

Medical device regulatory consultant Adrienne Lenz says FDA needs to develop a way for medical device manufacturers to transmit electronic 510(k) subm...

Medical Devices

Arthrex Paying $16 Million to Resolve Kickback Case

The Justice Department says Arthrex is paying $16 million to resolve a whistleblowers allegations of kickbacks leading to False Claims Act payments.

Medical Devices

Magstim 510(k) for Brain Stimulator Cleared

FDA clears a Magstim 510(k) for the Horizon 3.0, a transcranial magnetic stimulation device designed for the clinical setting.

Federal Register

Product-specific Draft Bioquivalence Guides

Federal Register notice: FDA makes available additional draft and revised draft product-specific guidances that provide product-specific recommendatio...

Federal Register

MedWatch Info Collection Extension

Federal Register notice: FDA sends to OMB an information collection extension entitled MedWatch: The FDA Medical Products Reporting Program.

Human Drugs

House Probes FDA/McKinsey Conflicts of Interest

The House Oversight and Reform Committee requests information on FDAs consulting contracts with McKinsey due to potential conflicts with consulting co...

Federal Register

Animal Drug Regs Amended for Application Actions

Federal Register notice: FDA amends its animal drug regulations to reflect application-related actions for new animal drug and abbreviated new animal ...

Human Drugs

Woodcock Upbeat on Generic/Biosimilar Programs

FDA acting commissioner Janet Woodcock says there continues to be huge opportunities for growth in the generic and biosimilar space.